GREY:ATBPF - Post by User
Comment by
2PackHabbiton Mar 13, 2018 12:37am
181 Views
Post# 27704721
RE:Point of interest...
RE:Point of interest... In 2016, Antibe announced the successful completion of a Phase 2 study of ATB-346 in patients with osteoarthritis of the knee. Twelve patients were treated once daily with 250 mg of ATB-346, which is only 1/6th of the typical daily dose of naproxen for treating osteoarthritis. The patients recorded their pain level one day prior to starting treatment and then again on days 4 and 10 of treatment using the WOMAC pain scale. The graph below shows the change in recorded pain level over the 10 days of the study. Previous studies show typical reductions in WOMAC pain scores for osteoarthritis patients taking celecoxib (Celebrex) of approximately 4 units following one week of treatment, with no additional improvement beyond that with continued treatment (Wittenberg et al., 2006). Thus, the average reduction of 7.6 units is quite impressive in that study population. https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2017/ATEV-Enrollment-Continuing-for-Phase-2b-Study-of-ATB-346-Data-Expected-in-1Q18-article/default.aspx